Skip to main content
Top
Published in: International Urology and Nephrology 5/2018

01-05-2018 | Nephrology - Original Paper

Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study

Authors: Nada Dimkovic, Georg Schlieper, Aleksandar Jankovic, Zivka Djuric, Marcus Ketteler, Tatjana Damjanovic, Petar Djuric, Jelena Marinkovic, Zoran Radojcic, Natasa Markovic, Jürgen Floege

Published in: International Urology and Nephrology | Issue 5/2018

Login to get access

Abstract

Purpose

Cardiovascular calcifications (CVC) are present in up to 70% of non-diabetic dialysis patients. Sparse data are available on predictors of very long-term outcomes of such patients. The Belgrade Aachen Study on Calcification in Hemodialysis patients (BASCH study) aimed to study this using a comprehensive CVC assessment.

Methods

We prospectively analyzed 220 hemodialysis patients followed for a mean of 76 months (median 73 months, range 6–160 months). We compared patients deceased from cardiovascular diseases (CVD) and survivors. Analyses included composite calcification scores (determined by combining ultrasound and X-ray analyses), demographic, clinical and laboratory data and pulse wave velocity (PWV). For survival analysis, patients were divided into group according to quartiles (Q).

Results

Compared to survivors, deceased patients from CVD were significantly older, more frequently hypertensive, had shorter dialysis times per week and lower Kt/V values, and they exhibited lower serum fetuin A, osteoprotegerin and hemoglobin as well as higher CRP levels. Composite calcification and Adragao scores were significantly higher in deceased patients from CVD as was PWV. Mean survival was 101 ± 47 months (Q1), 87 ± 51 month (Q2), 66 ± 48 (Q3) and 54 ± 45 months (Q4), p = 0.000. Cox multivariate regression analysis showed that independent predictors for cardiovascular mortality were composite calcification score in the range of third and fourth quartiles.

Conclusion

Composite calcification score emerged as significant predictors of long-term survival in our group of largely non-diabetic dialysis patient population, finding that should be confirmed by intervention studies.
Literature
1.
go back to reference Schlieper G, Brandenburg V, Djuric Z et al (2009) Risk factors for cardiovascular calcifications in nondiabetic Caucasian haemodialysis patients. Kidney Blood Press Res 32:161–168CrossRefPubMed Schlieper G, Brandenburg V, Djuric Z et al (2009) Risk factors for cardiovascular calcifications in nondiabetic Caucasian haemodialysis patients. Kidney Blood Press Res 32:161–168CrossRefPubMed
2.
go back to reference Ketteler M, Schlieper G, Floege J (2006) Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 47:1027–1034CrossRefPubMed Ketteler M, Schlieper G, Floege J (2006) Calcification and cardiovascular health: new insights into an old phenomenon. Hypertension 47:1027–1034CrossRefPubMed
4.
go back to reference Brandenburg VM, Sinha S, Specht P et al (2014) Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease mineral and bone disorder. Pediatr Nephrol 29:2289–2298CrossRefPubMed Brandenburg VM, Sinha S, Specht P et al (2014) Calcific uraemic arteriolopathy: a rare disease with a potentially high impact on chronic kidney disease mineral and bone disorder. Pediatr Nephrol 29:2289–2298CrossRefPubMed
5.
go back to reference Raggi P, Boulay A, Scott CT et al (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695–701CrossRefPubMed Raggi P, Boulay A, Scott CT et al (2002) Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol 39:695–701CrossRefPubMed
6.
go back to reference London G, Covic A, Goldsmith D et al (2011) Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney Int Suppl 1:10–12CrossRef London G, Covic A, Goldsmith D et al (2011) Arterial aging and arterial disease: interplay between central hemodynamics, cardiac work, and organ flow-implications for CKD and cardiovascular disease. Kidney Int Suppl 1:10–12CrossRef
12.
go back to reference Adragao T, Pires A, Lucas C et al (2004) A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19:1480–1488CrossRefPubMed Adragao T, Pires A, Lucas C et al (2004) A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant 19:1480–1488CrossRefPubMed
13.
go back to reference Damjanovic T, Djuric Z, Markovic N, Dimković S, Radojcic Z, Dimkovic N (2009) Screening of vascular calcifications in patients with end-stage renal diseases. Gen Physiol Biophys 28:277–283PubMed Damjanovic T, Djuric Z, Markovic N, Dimković S, Radojcic Z, Dimkovic N (2009) Screening of vascular calcifications in patients with end-stage renal diseases. Gen Physiol Biophys 28:277–283PubMed
14.
go back to reference Ix JH, Shlipak MG, Brandenburg VM et al (2006) Association between human fetuin-A and the metabolic syndrome: data from the heart and soul study. Circulation 113:1760–1767CrossRefPubMedPubMedCentral Ix JH, Shlipak MG, Brandenburg VM et al (2006) Association between human fetuin-A and the metabolic syndrome: data from the heart and soul study. Circulation 113:1760–1767CrossRefPubMedPubMedCentral
15.
go back to reference Schurgers LJ, Teunissen KJ, Knapen MH et al (2005) Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 25:1629–1633CrossRefPubMed Schurgers LJ, Teunissen KJ, Knapen MH et al (2005) Novel conformation-specific antibodies against matrix gamma-carboxyglutamic acid (Gla) protein: undercarboxylated matrix Gla protein as marker for vascular calcification. Arterioscler Thromb Vasc Biol 25:1629–1633CrossRefPubMed
16.
go back to reference Schlieper G (2014) Vascular calcification in chronic kidney disease: not all arteries are created equal. Kidney Int 85:501–503CrossRefPubMed Schlieper G (2014) Vascular calcification in chronic kidney disease: not all arteries are created equal. Kidney Int 85:501–503CrossRefPubMed
17.
go back to reference Floege J, Gillespie IA, Kronenberg F et al (2015) Development and validation of a predictive morality risk score from a European hemodialysis cohort. Kidney Int 87(5):996–1008CrossRefPubMedPubMedCentral Floege J, Gillespie IA, Kronenberg F et al (2015) Development and validation of a predictive morality risk score from a European hemodialysis cohort. Kidney Int 87(5):996–1008CrossRefPubMedPubMedCentral
18.
go back to reference Anker SD, Gillespie IA, Eckardt KU, On behalf the ARO Steering Committee (collaborators) et al (2016) Development and validation of cardiovascular risk scores for hemodialysis patients. Int J Cardiol 216:68–77CrossRefPubMed Anker SD, Gillespie IA, Eckardt KU, On behalf the ARO Steering Committee (collaborators) et al (2016) Development and validation of cardiovascular risk scores for hemodialysis patients. Int J Cardiol 216:68–77CrossRefPubMed
19.
go back to reference Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ (2004) Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 65:1790–1794CrossRefPubMed Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ (2004) Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int 65:1790–1794CrossRefPubMed
20.
go back to reference Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942CrossRefPubMed Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38:938–942CrossRefPubMed
21.
go back to reference Zoccali C, London G (2015) Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant 30:352–357CrossRefPubMed Zoccali C, London G (2015) Con: vascular calcification is a surrogate marker, but not the cause of ongoing vascular disease, and it is not a treatment target in chronic kidney disease. Nephrol Dial Transplant 30:352–357CrossRefPubMed
24.
go back to reference Ketteler M, Rothe K, Kruger T et al (2011) Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 7:509–5016CrossRefPubMed Ketteler M, Rothe K, Kruger T et al (2011) Mechanisms and treatment of extraosseous calcification in chronic kidney disease. Nat Rev Nephrol 7:509–5016CrossRefPubMed
25.
go back to reference Schafer C, Heiss A, Schwarz A et al (2003) The serum protein alpha 2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357–366CrossRefPubMedPubMedCentral Schafer C, Heiss A, Schwarz A et al (2003) The serum protein alpha 2-Heremans–Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 112:357–366CrossRefPubMedPubMedCentral
27.
go back to reference Ketteler M, Bongartz P, Westenfeld R et al (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361(9360):827–833CrossRefPubMed Ketteler M, Bongartz P, Westenfeld R et al (2003) Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet 361(9360):827–833CrossRefPubMed
28.
go back to reference Ix JH, Chertow GM, Shlipak MG et al (2007) Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the heart and soul study. Circulation 115:2533–2539CrossRefPubMedPubMedCentral Ix JH, Chertow GM, Shlipak MG et al (2007) Association of fetuin-A with mitral annular calcification and aortic stenosis among persons with coronary heart disease: data from the heart and soul study. Circulation 115:2533–2539CrossRefPubMedPubMedCentral
29.
go back to reference Moe SM, Reslerova M, Ketteler M et al (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67:2295–2304CrossRefPubMed Moe SM, Reslerova M, Ketteler M et al (2005) Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int 67:2295–2304CrossRefPubMed
30.
go back to reference Cranenburg EC, Brandenburg VM, Vermeer C et al (2009) Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 101:359–366PubMed Cranenburg EC, Brandenburg VM, Vermeer C et al (2009) Uncarboxylated matrix Gla protein (ucMGP) is associated with coronary artery calcification in haemodialysis patients. Thromb Haemost 101:359–366PubMed
31.
go back to reference Schlieper G, Westenfeld R, Krüger T et al (2011) Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD patients. J Am Soc Nephrol 22:387–395CrossRefPubMedPubMedCentral Schlieper G, Westenfeld R, Krüger T et al (2011) Circulating nonphosphorylated carboxylated matrix Gla protein predicts survival in ESRD patients. J Am Soc Nephrol 22:387–395CrossRefPubMedPubMedCentral
32.
go back to reference Kapustin AN, Davies JD, Reynolds JL et al (2011) Calcium regulates key components of vascular smooth muscle cells-derived matrix vesicles to enhance mineralization. Circ Res 109:e1–e12CrossRefPubMed Kapustin AN, Davies JD, Reynolds JL et al (2011) Calcium regulates key components of vascular smooth muscle cells-derived matrix vesicles to enhance mineralization. Circ Res 109:e1–e12CrossRefPubMed
33.
go back to reference Hofbauer LC, Schoppet M (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 358:257–259CrossRefPubMed Hofbauer LC, Schoppet M (2001) Osteoprotegerin: a link between osteoporosis and arterial calcification? Lancet 358:257–259CrossRefPubMed
34.
go back to reference Eknoyan G, Beck GJ, Cheung AK et al (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347(25):2010–2019CrossRefPubMed Eknoyan G, Beck GJ, Cheung AK et al (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347(25):2010–2019CrossRefPubMed
35.
go back to reference Schlieper G, Brandenburg V, Djuric Z et al (2007) Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients? Dtsch Med Wochenschr 132:1820–1824CrossRefPubMed Schlieper G, Brandenburg V, Djuric Z et al (2007) Is there a correlation between C-reactive protein and calcification inhibitors with cardiovascular parameters and risk factors in hemodialysis patients? Dtsch Med Wochenschr 132:1820–1824CrossRefPubMed
36.
go back to reference Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European hemodialysis population. Nephrol Dial Transplant 26:1948–1955CrossRefPubMed Floege J, Kim J, Ireland E et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European hemodialysis population. Nephrol Dial Transplant 26:1948–1955CrossRefPubMed
Metadata
Title
Prognostic value of cardiovascular calcifications in hemodialysis patients: a longitudinal study
Authors
Nada Dimkovic
Georg Schlieper
Aleksandar Jankovic
Zivka Djuric
Marcus Ketteler
Tatjana Damjanovic
Petar Djuric
Jelena Marinkovic
Zoran Radojcic
Natasa Markovic
Jürgen Floege
Publication date
01-05-2018
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 5/2018
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-018-1821-1

Other articles of this Issue 5/2018

International Urology and Nephrology 5/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.